Cancer Research and Treatment

Original Articles

Evaluating Immunotherapy Outcomes in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer (KCSG LU23-15): Yun-Gyoo Lee, Tae-Hwan Kim, Du-Young Kang, Ji Hyun Park, Kyoungmin Lee, Juwhan Choi, Sung Yong Lee, Ji Won Lee, Yoon Ji Choi, Ah-reum Lim, Jung Yoon Choi, Jung Sun Kim, Hee Kyung Ahn, Jin-Hyuk Choi, Eun Joo Kang; Received May 10, 2026 Accepted August 13, 2026 Published online August 14, 2026; DOI: https://doi.org/10.4143/crt.2026.0507 [Accepted]

Abstract PDF: Purpose
Chemoimmunotherapy has improved outcomes in extensive-stage small-cell lung cancer (ES-SCLC), but its benefit in older adults remains uncertain because this population is underrepresented in clinical trials. We evaluated the real-world efficacy of first-line atezolizumab plus etoposide-carboplatin according to age in patients with ES-SCLC.
Materials and Methods
We conducted a multicenter retrospective study across seven Korean institutions and identified patients with ES-SCLC treated between 2016 and 2022 with atezolizumab plus etoposide-carboplatin or etoposide-platinum chemotherapy alone. Patients with recurrence after prior limited-stage disease or incomplete records were excluded. End points were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), assessed using Kaplan-Meier methods and Cox regression models.
Results
Among 550 identified patients, 538 were included: 247 received atezolizumab plus chemotherapy and 291 received chemotherapy alone. Overall, 111 patients (20.2%) were aged 75–80 and 57 (10.4%) were older than 80years. In the overall population, atezolizumab was associated with improved PFS (hazard ratio [HR], 0.78; 95% CI, 0.65 to 0.93; p=0.006) and OS (HR, 0.76; 95% CI, 0.63 to 0.93; p=0.006). Age-stratified analyses showed significant PFS benefit only in patients aged 70–75 (HR, 0.67; p=0.049) and significant OS benefit only in patients aged 65–70 (HR, 0.65; p=0.044). Beyond 75 years, neither PFS nor OS was significantly improved. Patients aged ≥75years also had lower ORR and more progressive or non-evaluable disease compared with <75years.
Conclusion
The clinical benefit of adding atezolizumab appears attenuated in ES-SCLC patients age 75 years or older, supporting careful selection and age-adapted treatment strategies.

365 View
31 Download

Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13): Jwa Hoon Kim, Sang Joon Shin, Woo Kyun Bae, Se Hyun Kim, Jin Young Kim, Hyeon-Su Im, In-Ho Kim, Il Hwan Kim, Kwonoh Park, Eo Jin Kim, Mihong Choi, Joo Han Lim, Hyunho Kim, Kyoungmin Lee, Hyo-Jeong Kim, Jungmin Jo, Hyo Jin Lee, Dalyong Kim, Byeong Seok Sohn, Inkeun Park, Ji Hyun Park; Received August 8, 2025 Accepted October 11, 2025 Published online October 13, 2025; DOI: https://doi.org/10.4143/crt.2025.846 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
We investigated the real-world efficacy of first-line nivolumab plus ipilimumab (NI) and its predictive clinicopathological biomarkers in patients with advanced renal cell carcinoma (aRCC).
Materials and Methods
We retrospectively analyzed 466 patients with aRCC who started first-line NI between 2019 and 2023 at 21 Korean tertiary hospitals. The primary outcome was objective response rate (ORR). Secondary outcomes were duration of response (DoR), progression-free survival (PFS), overall survival (OS), and identification of practical clinicopathological biomarkers.
Results
Median age of patients was 65 years, and 77.7% were male. ORR was 44.8% including 5.2% of complete response, and median DoR was 39.8 months. Male sex and lung metastasis were predictive markers of objective response, and achieving complete response was significantly associated with a longer DoR (p=0.03). With a median follow-up duration of 23.7 months, the median PFS and OS were 11.5 and 44.2 months, respectively. Full exposure to 4 cycles of ipilimumab was significantly associated with better PFS and OS. Durable response could significantly predict better OS, whereas multiple metastatic sites (≥ 4) and poor IMDC risk were two independent predictors for inferior OS. Among the 50 patients who completed 2 years of NI treatment, continuation of nivolumab beyond 2 years has marginally improved OS (p=0.09).
Conclusion
First-line NI showed comparable and competent efficacy in Korean patients with aRCC. We suggest completing full exposure to ipilimumab and durable response as practical predictors of enriched benefits of NI in our real-world.

1,964 View
165 Download

Hematologic malignancy

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK: Sora Kang, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Yoon Sei Lee, Chan-Sik Park, Heounjeong Go, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Seok Jin Kim, Won Seog Kim, Sang Eun Yoon, Young Hyeh Ko, Cheolwon Suh; Cancer Res Treat. 2023;55(1):314-324. Published online March 31, 2022; DOI: https://doi.org/10.4143/crt.2022.015

Abstract PDF Supplementary Material PubReader ePub

Purpose
Prognostic Index for Natural Killer Lymphoma (PINK) is the most widely accepted prognostic model for patients withextranodal natural killer/T-cell lymphoma (ENKTL) treated with non-anthracycline–based therapy. We aimed to evaluate the prognostic implications of serum β-2 microglobulin (β2M) in the context of PINK and proposed a new prognostic model.
Materials and Methods
A total of 138 patients who were newly diagnosed with ENKTL and treated with non-anthracycline-based chemotherapy were identified. The cut-off value of high serum β2M was calculated by maximal-chi square methods (4.1 mg/L). A new prognostic model incorporating serum β2M into PINK was proposed and validated in an independent validation cohort (n=88).
Results
The patients’ median age was 53.5 years (range, 19 to 80 years). Patients with high serum β2M levels had significantly worse overall survival (OS) and progression-free survival (PFS). In multivariate analysis, high serum β2M was an independent adverse prognostic factor for OS. A new PINK-B (Prognostic Index for Natural Killer Lymphoma-serum β-2 microglobulin) model stratifiedpatients into three groups with distinct OS and PFS in the training cohort (3-year OS, 84.1% [95% confidence interval, 75.1 to 94.2], 46.8% [36.1 to 60.8] and 17.6% [6.3 to 49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4 to 83.8], 35.9% [25.9 to 49.8], and 7.35% [1.1 to 46.7] for the low-, intermediate-, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort.
Conclusion
Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into daily clinical practice.

Citations

Citations to this article as recorded by

Epstein‐Barr Virus‐positive NK/T‐cell Malignancies in Poland: Distinctive Features, Therapeutic Strategies, and Survival Insights—The Real‐world Retrospective Report of the Polish Lymphoma Research Group
Kateryna Filonenko, Ewa Paszkiewicz‐Kozik, Joanna Drozd‐Sokolowska, Marcin Szymanski, Agnieszka Giza, Anna Kopinska, Ewa Chmielowska, Jan Maciej Zaucha
Asia-Pacific Journal of Clinical Oncology.2026; 22(4): 584. CrossRef
A Bloody Mimic of Crohn’s Disease: Primary Intestinal EBV-Positive NK/T-Cell Lymphoma
Alexander Iacobucci, Joshua Norman, Elsie Ennin, Sebastian Fernandez-Pol, George Triadafilopoulos, Grant Barber
Digestive Diseases and Sciences.2026;[Epub] CrossRef
Correlation analysis of the serum LDH, b2-MG, IL-2R and IL-10 levels in lymphoma patients
Xifeng Xu, Yilin Wen, Rongquan Yao, Jianping Zhang
Journal of Medical Biochemistry.2026; 45(7): 1641. CrossRef
Beta-2 microglobulin in lymphoma
Gaurav Gupta, Muhammad Afzal, Ahsas Goyal, G. PadmaPriya, Manish Srivastava, Kattela Chennakesavulu, Biswaranjan Mohanty, A. Rekha, Avijit Mazumder, Kavita Goyal, Haider Ali, Moyad Shahwan
Clinica Chimica Acta.2025; 576: 120418. CrossRef
Asparaginase Hypersensitivity Reactions in NK/T-Cell Lymphomas
Javier Varela Gonzalez-Aller, Pablo Nadal, Salome Cañizares, Carmen Muñoz, Anna Valer, Eva Gonzalez-Barca, Eva Domingo, Ana Sureda, Silvana Novelli
Clinics and Practice.2025; 15(11): 211. CrossRef
Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma
Yun Hui, Yingjun Gao, Jiawei Li, Qingtao Kong, Yuanyuan Duan, Haibo Liu, Fang Liu, Hong Sang
Annals of Hematology.2024; 103(4): 1285. CrossRef
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantin
Cancers.2024; 16(2): 238. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase
Ziyuan Shen, Xudong Zhang, Yujie Li, Xicheng Chen, Xing Xing, Hao Zhang, Jingjing Ye, Ling Wang, Tao Jia, Taigang Zhu, Yuqing Miao, Chunling Wang, Hui Liu, Liang Wang, Wei Sang
Future Oncology.2024; 20(28): 2071. CrossRef

12,418 View
143 Download
10 Web of Science
9 Crossref

Hematologic Malignancy

Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels: Hyung-Don Kim, Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Dok-Hyun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh; Cancer Res Treat. 2021;53(3):847-856. Published online December 17, 2020; DOI: https://doi.org/10.4143/crt.2020.1060

Abstract PDF Supplementary Material PubReader ePub

Purpose
We aimed to investigate the prognostic value of serum β2-microglobulin for patients with Burkitt lymphoma (BL) and to propose a risk-stratifying classification system.
Materials and Methods
A prospective registry-based cohort study of BL patients treated with dose-intensive or effective dose-adjusted chemotherapies (n=81) was conducted. Survival outcomes were compared based on previously reported risk groups and/or serum β2-microglobulin levels. A risk-stratifying classification system incorporating serum β2-microglobulin levels was proposed and validated in an independent validation cohort (n=60).
Results
The median age was 47 years, and 57 patients (70.4%) were male. Patients with high serum β2-microglobulin levels (> 2 mg/L) had significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.01 for both). Serum β2-microglobulin levels further stratified patients in the low-risk and high-risk groups in terms of PFS (p=0.010 and p=0.044, respectively) and OS (p=0.014 and p=0.026, respectively). Multivariate analyses revealed that a high serum β2-microglobulin level (> 2 mg/L) was independently associated with a shorter PFS (hazards ratio [HR], 3.56; p=0.047) and OS (HR, 4.66; p=0.043). The new classification system incorporating the serum β2-microglobulin level allowed the stratification of patients into three distinct risk subgroups with 5-year OS rates of 100%, 89.5%, and 62.5%. In an independent cohort of BL, the system was validated by stratifying patients with different survival outcomes.
Conclusion
Serum β2-microglobulin level is an independent prognostic factor for BL patients. The proposed β2-microglobulin–based classification system could stratify patients with distinct survival outcomes, which may help define appropriate treatment approaches for individual patients.

Citations

Citations to this article as recorded by

A novel prognostic model for primary central nervous system lymphoma incorporating clinico-laboratory parameters
Yeokyeong Shin, Jaewon Hyung, Shin Kim, Kyoungmin Lee, Chan-Sik Park, Heounjeong Go, In Hye Song, Jae Seung Kim, Minyoung Oh, Sang-Wook Lee, Sangjoon Chong, Sang Woo Song, Young-Hoon Kim, Young Hyun Cho, Seok Ho Hong, Jeong Hoon Kim, Ji Sung Lee, Eun Jin
Neuro-Oncology.2026; 28(3): 741. CrossRef
Serum Protein Profiling of Patients at Risk to Develop Gastric Disease Based on a DSC Test
Ombretta Repetto, Filippo Sperti, Mariangela De Zorzi, Veronica Paduano, Stefano Realdon, Agostino Steffan, Renato Cannizzaro, Valli De Re
International Journal of Molecular Sciences.2026; 27(10): 4464. CrossRef
Predictors of survival among children with Burkitt lymphoma treated at a single center in Tanzania: a retrospective cohort study
Aika A. Shoo, Advera I. Ngazia, Nahya S. Masoud, Shakilu Jumanne, James J. Yahaya
Hematology, Transfusion and Cell Therapy.2026; 48(3): 106496. CrossRef
Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review
Aythami de Armas‐Castellano, Diego Infante‐Ventura, Tasmania del Pino‐Sedeño, Yadira González Hernández, Raul Quiros, Beatriz León‐Salas, Vincent Ribrag, María M. Trujillo‐Martín
Cancer Medicine.2025;[Epub] CrossRef
Predictive Value of Serum β2-Microglobulin for 28-Day Mortality in Sepsis Patients in the Emergency Department
Xiangqun Zhang, Long Yang, Yu Gu, Junyuan Wu, Xue Mei, Shubin Guo
Infection and Drug Resistance.2025; Volume 18: 2365. CrossRef
The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients
Ze Jin, Yi Miao, Jie Zhang, Jing Zhang, Chunling Wang, Xuzhang Lu, Yuqing Miao, Miao Sun, Yunping Zhang, Yun Zhuang, Haiwen Ni, Jingyan Xu, Wanchuan Zhuang, Min Zhao, Jianfeng Zhu, Min Xu, Guoqiang Lin, Haiying Hua, Xiaoyan Xie, Maozhong Xu, Tao Jia, Liji
Annals of Hematology.2024; 103(7): 2257. CrossRef
Prognostic Value of18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma
Yu Luo, Zhun Huang, Zihan Gao, Bingbing Wang, Yanwei Zhang, Yan Bai, Qingxia Wu, Meiyun Wang
Korean Journal of Radiology.2024; 25(2): 189. CrossRef
The Role of Beta2-Microglobulin in Central Nervous System Disease
Zhen-Yuan Liu, Feng Tang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
Cellular and Molecular Neurobiology.2024;[Epub] CrossRef
Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study
Zhen-Yuan Liu, Feng Tang, Jing Wang, Jin-Zhou Yang, Xi Chen, Ze-Fen Wang, Zhi-Qiang Li
BMC Cancer.2024;[Epub] CrossRef
Serum beta2-microglobulin and peripheral blood eosinophils for the assessment of severity and prognosis with omicron variant COVID-19 infection
Jie Tan, Hanxi Fang, Xiao Hu, Ming Yue, Junling Yang
Frontiers in Molecular Biosciences.2024;[Epub] CrossRef
A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis
Zhentian Wu, Chenyi Wang, Yao Lyu, Zheshen Lin, Ming Lu, Shixiong Wang, Bingxuan Wang, Na Yang, Yeye Li, Jianhong Wang, Xiaohui Duan, Na Zhang, Jing Gao, Yuan Zhang, Miaowang Hao, Zhe Wang, Guangxun Gao, Rong Liang
Frontiers in Oncology.2023;[Epub] CrossRef
Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
Ning-Chun Chen, Hung Chang, Hsiao-Wen Kao, Che-Wei Ou, Ming-Chung Kuo, Po-Nan Wang, Tung-Liang Lin, Jin-Hou Wu, Yu-Shin Hung, Yi-Jiun Su, Yuen-Chin Ong, Hsuan-Jen Shih
Clinical and Experimental Medicine.2023; 23(7): 3759. CrossRef
Tuberculosis combined with Burkitt lymphoma in a kidney transplant recipient: A case report and literature review
Jian-Nan Hu, Mu-Qing Yu, Li-Juan Hua, Chen Bao, Qian Liu, Chao Liu, Zi-Ling Li, Xi Wang, Shu-Yun Xu
Medicine.2023; 102(18): e33671. CrossRef
Elevated serum beta-2 microglobulin level predicts short-term poor prognosis of patients with de novo acute omicron variant COVID-19 infection
Shengping Gong, Ruishuang Ma, Ting Zhu, Xiaoqin Ge, Rongrong Xie, Qingsong Tao, Cong Shi
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers
Yajiao Liu, Li Sheng, Haiying Hua, Jingfen Zhou, Ying Zhao, Bei Wang
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified
Hyung-Don Kim, Hyungwoo Cho, Byeong Seok Sohn, Chan-Sik Park, Jooryung Huh, Jin Sook Ryu, Sang-Wook Lee, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim, Cheolwon Suh
Leukemia & Lymphoma.2022; 63(1): 124. CrossRef

9,166 View
153 Download
16 Web of Science
16 Crossref

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Kyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoo; Cancer Res Treat. 2020;52(1):254-262. Published online July 9, 2019; DOI: https://doi.org/10.4143/crt.2019.190

Abstract PDF Supplementary Material PubReader ePub

Purpose
Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progressed on 1L nab-P+GEM.
Materials and Methods
Among the 203 patients previously treated with 1L nab-P+GEM for mPDAC at Asan Medical Center, between February and December 2016, records of 120 patients receiving 2L chemotherapy after progression on nab-P+GEM were retrospectively reviewed. The response rate and survival were evaluated along with analysis of prognostic factors.
Results
Fluoropyrimidine-oxaliplatin doublets (FOLFOX or XELOX) were used in 78 patients (65.0%), fluoropyrimidine monotherapy in 37 (30.8%), and liposomal irinotecan plus fluorouracil in two (1.7%). The median progression-free survival (PFS) and overall survival (OS) were 3.29 months and 7.33 months from the start of 2L therapy. Fluoropyrimidine-oxaliplatin regimens and fluoropyrimidine monotherapy did not yield significantly different median PFS (2.89 months vs. 3.81 months, p=0.40) or OS (7.04 months vs. 7.43 months, p=0.86). A high neutrophil-lymphocyte ratio (> 2.2) and a short time to progression with 1L nab-P+GEM (< 6.4 months) were independent prognostic factors of poor OS with 2L therapy.
Conclusion
2L fluoropyrimidine-oxaliplatin doublets and fluoropyrimidine monotherapy after failure of 1L nab-P+GEM had modest efficacy, with no differences in treatment outcomes between them. Further investigation is warranted for the optimal 2L chemo-regimens and sequencing of systemic chemotherapy for patients with mPDAC.

Citations

Citations to this article as recorded by

Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study
Camille Evrard, Antoine Pelras, Simon Rivet, Jean-Baptiste Bachet, Olivier Dubreuil, Anne-Laure Pointet, Julien Taieb, Widad Lahlou, Alix Portal, Céline Lepère, Thierry Lecomte, Romain Chautard, Nicolas Williet, Jean-Marc Phelip, Clélia Coutzac, Emilie So
The Oncologist.2025;[Epub] CrossRef
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Brandon M. Huffman, Atrayee Basu Mallick, Nora K. Horick, Andrea Wang-Gillam, Peter Joel Hosein, Michael A. Morse, Muhammad Shaalan Beg, Janet E. Murphy, Sharon Mavroukakis, Anjum Zaki, Benjamin L. Schlechter, Hanna Sanoff, Christopher Manz, Brian M. Wolp
JAMA Network Open.2023; 6(1): e2249720. CrossRef
Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
Journal of Korean Medical Science.2022;[Epub] CrossRef
EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case–control study
Sabrina Gloria Giulia Testoni, Maria Chiara Petrone, Michele Reni, Clelia Di Serio, Paola Maria Rancoita, Gemma Rossi, Gianpaolo Balzano, Walter Linzenbold, Markus Enderle, Emanuel Della-Torre, Francesco De Cobelli, Massimo Falconi, Gabriele Capurso, Paol
Endoscopic Ultrasound.2022; 11(5): 383. CrossRef
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Jaime Feliu, Mónica Jorge Fernández, Teresa Macarulla, Bartomeu Massuti, Ana Albero, José Federico González González, Guillermo Quintero-Aldana, Juan Ignacio Delgado-Mingorance, Ana Fernández Montes, Carmen García Piernavieja, Manuel Valladares-Ayerbes, A
Cancer Chemotherapy and Pharmacology.2021; 87(4): 543. CrossRef
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
H.S. Park, B. Kang, H.J. Chon, H.-S. Im, C.-K. Lee, I. Kim, M.J. Kang, J.E. Hwang, W.K. Bae, J. Cheon, J.O. Park, J.Y. Hong, J.H. Kang, J.H. Kim, S.H. Lim, J.W. Kim, J.-W. Kim, C. Yoo, H.J. Choi
ESMO Open.2021; 6(2): 100049. CrossRef
Pancreatic adenocarcinoma: Beyond first line, where are we?
Sara Cherri, Silvia Noventa, Alberto Zaniboni
World Journal of Gastroenterology.2021; 27(17): 1847. CrossRef
Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma
Mandana Kamgar, Sakti Chakrabarti, Aditya Shreenivas, Ben George
Surgical Oncology Clinics of North America.2021; 30(4): 673. CrossRef
Treatment optimization of locally advanced and metastatic pancreatic cancer (Review)
Anabela Barros, Catarina Pulido, Manuela Machado, Maria Brito, Nuno Couto, Olga Sousa, Sónia Melo, Hélder Mansinho
International Journal of Oncology.2021;[Epub] CrossRef
Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
Emma Gränsmark, Nellie Bågenholm Bylin, Hakon Blomstrand, Mats Fredrikson, Elisabeth Åvall-Lundqvist, Nils O. Elander
Frontiers in Oncology.2020;[Epub] CrossRef
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina De
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Laparoscopic repeated pancreatectomy for isolated local recurrence in remnant pancreas following laparoscopic radical pancreatectomy for pancreatic ductal adenocarcinoma: Two cases report
Munseok Choi, Suk Jun Lee, Dong-Min Shin, Ho Kyoung Hwang, Woo Jung Lee, Chang Moo Kang
Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(4): 542. CrossRef
Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
L. I. Moskvicheva, L. V. Bolotina
Research and Practical Medicine Journal.2020; 7(4): 118. CrossRef

12,855 View
328 Download
11 Web of Science
13 Crossref

Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth: Jaehyun Lee, Yong Jae Shin, Kyoungmin Lee, Hee Jin Cho, Jason K. Sa, Sang-Yun Lee, Seok-Hyung Kim, Jeongwu Lee, Yeup Yoon, Do-Hyun Nam; Cancer Res Treat. 2018;50(3):1009-1022. Published online November 10, 2017; DOI: https://doi.org/10.4143/crt.2017.315

Abstract PDF Supplementary Material PubReader ePub

Purpose
Glioblastoma (GBM) is classified as one of the most aggressive and lethal brain tumor. Great strides have been made in understanding the genomic and molecular underpinnings of GBM, which translated into development of new therapeutic approaches to combat such deadly disease. However, there are only few therapeutic agents that can effectively inhibit GBM invasion in a clinical framework. In an effort to address such challenges, we have generated anti-SEMA3A monoclonal antibody as a potential therapeutic antibody against GBM progression.
Materials and Methods
We employed public glioma datasets, Repository of Molecular Brain Neoplasia Data and The Cancer Genome Atlas, to analyze SEMA3AmRNA expression in human GBM specimens. We also evaluated for protein expression level of SEMA3A via tissue microarray (TMA) analysis. Cell migration and proliferation kinetics were assessed in various GBM patient-derived cells (PDCs) and U87-MG cell-line for SEMA3A antibody efficacy. GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo.
Results
By combining bioinformatics and TMA analysis, we discovered that SEMA3A is highly expressed in human GBM specimens compared to non-neoplastic tissues. We developed three different anti-SEMA3A antibodies, in fully human IgG form, through screening phage-displayed synthetic antibody library using a classical panning method. Neutralization of SEMA3A significantly reduced migration and proliferation capabilities of PDCs and U87-MG cell line in vitro. In PDX models, treatment with anti-SEMA3A antibody exhibited notable tumor inhibitory effect through down-regulation of cellular proliferative kinetics and tumor-associated macrophages recruitment.
Conclusion
In present study, we demonstrated tumor inhibitory effect of SEMA3A antibody in GBM progression and present its potential relevance as a therapeutic agent in a clinical framework.

Citations

Citations to this article as recorded by

Leveraging Network-Based Transcriptome Analysis from Mouse Tumor Models and Explainable Artificial Intelligence to Advance the Understanding of the Antitumor Activity of Lenvatinib
Haruna Imamura, Sufeng Chiang, Megumi Kuronishi, Yasuhiro Funahashi, Taiko Nishino, Ayako Yachie
Cancers.2026; 18(7): 1067. CrossRef
Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing
Niek van Bree, Ann-Sophie Oppelt, Susanne Lindström, Leilei Zhou, Lola Boutin, Beth Coyle, Fredrik J Swartling, John Inge Johnsen, Lars Bräutigam, Margareta Wilhelm
Neuro-Oncology.2025; 27(3): 779. CrossRef
Boric Acid Induces Oxidative Damage and Apoptosis Through SEMA3A/PLXNA1/NRP1 Signalling Pathway in U251 Glioblastoma Cell
Ezgi Kar, Zeynep Övenler, Ceyhan Hacıoğlu, Fatih Kar
Journal of Cellular and Molecular Medicine.2025;[Epub] CrossRef
HIC2 suppresses glioblastoma progression via transcriptional repression of SEMA3A and inhibition of TGF-β signaling
Liang Zhang, Jiahao Yang, Xueying Ke, Nan Huang, Dong Zhou, Haiping Cai
Free Radical Biology and Medicine.2025; 240: 674. CrossRef
The Aptamer bi-(AID-1-T) Synergizes with Radiation to Inhibit Proliferation of Human Glioma Cells
Svetlana Pavlova, Ksenia Rubetskaya, Lika Fab, Ekaterina Savchenko, Nadezhda Samoylenkova, Alexander Revishchin, Anastasia Ryabova, Natalia Antipina, Mikhail Galkin, Andrey Golanov, Dmitry Usachev, Alexey Kopylov, Galina Pavlova
Pharmaceutics.2025; 17(11): 1442. CrossRef
Sema3A Affect Osteolytic Bone Metastasis of Non-small Cell Lung Cancer
Wei Wang, Kaicheng Shen, Ruyan Liu, Qi Zhou
Recent Patents on Anti-Cancer Drug Discovery.2025; 20(4): 589. CrossRef
Expression of semaphorin 3A (SEMA3A) in breast cancer subtypes
Natalia Andryszak, Paweł Kurzawa, Monika Krzyżaniak, Marek Ruchała, Michał Nowicki, Dariusz Iżycki, Rafał Czepczyński
Scientific Reports.2024;[Epub] CrossRef
Hypoxia-induced Semaphorin 3A promotes the development of endometriosis through regulating macrophage polarization
Ruyu Yang, Fan Yang, Yajing Wei, Biqi Huang, Tiefeng Cao, Hao Tan, Duo Liu, Qiuyu Zou, Jinjuan Wen, Lei Wen, Xi Lu, Changyang Yu, Heng Cai, Xiaofei Xie, Shaoru Jiang, Shuzhong Yao, Yanchun Liang
International Immunopharmacology.2024; 138: 112559. CrossRef
Semaphorins: Novel Insights on Their Emerging Multifaceted Roles in the Evolving Landscape of Breast Cancer
Ts. Popov
Acta Medica Bulgarica.2024; 51(s2): 153. CrossRef
Role of semaphorins, neuropilins and plexins in cancer progression
P. Fernández-Nogueira, P. Linzoain- Agos, M. Cueto-Remacha, I. De la Guia-Lopez, L. Recalde-Percaz, A. Parcerisas, P. Gascon, N. Carbó, A. Gutierrez-Uzquiza, G. Fuster, P. Bragado
Cancer Letters.2024; 606: 217308. CrossRef
Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance
Radhika Aiyappa-Maudsley, Louis F. V. McLoughlin, Thomas A. Hughes
International Journal of Molecular Sciences.2023; 24(17): 13093. CrossRef
Pinpointing the interaction site between semaphorin‐3A and its inhibitory peptide
Kevin Kretschmer, Jan Stichel, Kathrin Bellmann‐Sickert, Lars Baumann, Donald Bierer, Bernd Riedl, Annette G. Beck‐Sickinger
Journal of Peptide Science.2023;[Epub] CrossRef
Semaphorin 3A influences neuronal processes that are altered in patients with autism spectrum disorder: Potential diagnostic and therapeutic implications
Carmela Matrone, Gabriella Ferretti
Neuroscience & Biobehavioral Reviews.2023; 153: 105338. CrossRef
Semaphorins as Potential Immune Therapeutic Targets for Cancer
Jun Jiang, Fang Zhang, Yi Wan, Ke Fang, Ze-dong Yan, Xin-ling Ren, Rui Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Semaphorin Regulation by the Chromatin Remodeler CHD7: An Emerging Genetic Interaction Shaping Neural Cells and Neural Crest in Development and Cancer
Antonella Lettieri, Roberto Oleari, Alyssa J. J. Paganoni, Cristina Gervasini, Valentina Massa, Alessandro Fantin, Anna Cariboni
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
New Angiogenic Regulators Produced by TAMs: Perspective for Targeting Tumor Angiogenesis
Irina Larionova, Elena Kazakova, Tatiana Gerashchenko, Julia Kzhyshkowska
Cancers.2021; 13(13): 3253. CrossRef
Research Progress About Glioma Stem Cells in the Immune Microenvironment of Glioma
Xiangyu Li, Ming Liu, Junfeng Zhao, Tong Ren, Xin Yan, Lijun Zhang, Xun Wang
Frontiers in Pharmacology.2021;[Epub] CrossRef
The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer
Tuba Karpuz, Murat Araz, Levent Korkmaz, Ibrahim Kılınc, Sidika Findik, Mustafa Karaagaç, Melek Karakurt Eryilmaz, Mehmet Artac
Journal of Gastrointestinal Cancer.2020; 51(2): 491. CrossRef
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Carla Riera-Domingo, Annette Audigé, Sara Granja, Wan-Chen Cheng, Ping-Chih Ho, Fátima Baltazar, Christian Stockmann, Massimiliano Mazzone
Physiological Reviews.2020; 100(1): 1. CrossRef
SEMA3AExon 9 Expression Is a Potential Prognostic Marker of Unfavorable Recurrence-Free Survival in Patients with Tongue Squamous Cell Carcinoma
Tian Tian, Lingnan Zhang, Kailiang Tang, Aiqin Wang, Jing Wang, Jingjing Wang, Fang Wang, Wenlong Wang, Xiangrui Ma
DNA and Cell Biology.2020; 39(4): 555. CrossRef
Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening
Kayoung Shin, Hyemi Shin, Hee Jin Cho, Hyunju Kang, Jin-Ku Lee, Yun Jee Seo, Yong Jae Shin, Donggeon Kim, Harim Koo, Doo-Sik Kong, Ho Jun Seol, Jung-Il Lee, Hye Won Lee, Do-Hyun Nam
Cancers.2020; 12(3): 549. CrossRef
A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches
Ishtiaque Ahammad
Biophysical Reviews.2020; 12(5): 1233. CrossRef
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Christopher A Chuckran, Chang Liu, Tullia C Bruno, Creg J Workman, Dario AA Vignali
Journal for ImmunoTherapy of Cancer.2020; 8(2): e000967. CrossRef
Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression
Shira Toledano, Inbal Nir-Zvi, Rotem Engelman, Ofra Kessler, Gera Neufeld
International Journal of Molecular Sciences.2019; 20(3): 556. CrossRef
Multifaceted Functional Role of Semaphorins in Glioblastoma
Cristiana Angelucci, Gina Lama, Gigliola Sica
International Journal of Molecular Sciences.2019; 20(9): 2144. CrossRef

13,114 View
392 Download
27 Web of Science
25 Crossref

Case Report

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient: Eunji Choi, Jae-Cheol Jo, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Jooryung Huh, Chan-Sik Park, Sang Wook Lee, Cheolwon Suh; Cancer Res Treat. 2015;47(3):539-543. Published online September 11, 2014; DOI: https://doi.org/10.4143/crt.2013.245

Abstract PDF PubReader ePub

Here we report a case of a 76-year-old man with diffuse large B-cell lymphoma (DLBCL) with simultaneous involvement of the right breast and left testicle. The patient underwent complete resection of the involved testis, followed by immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) and prophylactic radiotherapy to the contralateral testis. Following this multimodal therapy, he achieved a complete response. This is a rare case of DLBCL involving both the breast and the testis in a male patient.

Citations

Citations to this article as recorded by

Case Report: Difficulties in diagnosis of myeloid sarcoma of the breast by core needle biopsy
Demian Wu, Xiaolan Li, Xiaoxue Tian, Ting Xu, Qiyao Ge, Shuai Luo, Jinjing Wang
Frontiers in Medicine.2025;[Epub] CrossRef
Bilateral Primary Testicular Lymphoma with Retroperitoneal and Possible CNS Involvement: A Rare Case Report
Poosarla Ram Sohan, Chandrashekhar Mahakalkar, Shruthi Bikkumalla, Srinivasa Reddy, Akansha Hatewar, Sparsh Dixit
International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 487. CrossRef
Rare incidence of diffuse large B-cell lymphoma (DLBCL) with bilateral breast and testicular involvement in a male patient: A case report and review of the literature
Sarah Ayad, Anuraag Sah, Kirolos Gergis, Michelle Cholankeril
Current Problems in Cancer: Case Reports.2022; 5: 100142. CrossRef
Primary breast lymphoma in males: Incidence, demographics, prognostic factors, survival, and comparisons with females
Jie Zhang, Binbin Ma, Hong Ji, Rong Guo
Frontiers in Surgery.2022;[Epub] CrossRef
Diffuse Large B-Cell Breast Lymphoma: A Case Series
Afaf H Al Battah, Einas A Al Kuwari, Zsolt Hascsi, Abdulqadir J Nashwan, Halima Elomari, Hisham Elsabah, Safa Al Azawi, Samah Kohla, Dina Soliman, Mohamed A Yassin
Clinical Medicine Insights: Blood Disorders.2017; 10: 1179545X1772503. CrossRef

14,942 View
69 Download
4 Web of Science
5 Crossref

First
Prev
Page of 1
Next
Last

Search